StockCIK 1070081

PTC THERAPEUTICS, INC. (PTCT): Insider Trades and Fund Holdings

In the past 12 months, PTC THERAPEUTICS, INC. insiders reported 0 open-market purchases worth $0 and 15 sales worth $7.75M; 15 of the sales were reported as made under a 10b5-1 trading plan.

0Insider buys, 12 months

$0Bought by insiders, 12 months

$7.75MSold by insiders, 12 months

1Tracked funds holding

Recent insider trades

Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 16, 2026.

Recent PTCT insider trades
Filed	Traded	Insider	Role	Type	Shares	Price ($)	Value	Holding	Filing
Oct 16	Oct 14	Michael SchmertzlerDirector	Director (ind.)	▼ SELL10b5-1	2,500	59.61	$149K	−0.2%	Form 4 ↗
Oct 13	Oct 9	Mark Elliott BouldingGeneral Counsel	General Counsel	▼ SELL10b5-1	192	64.26	$12K	−0.2%	Form 4 ↗
Oct 9	Oct 7	Michael SchmertzlerDirector	Director (ind.)	▼ SELL10b5-1	2,500	63.39	$158K	−0.2%	Form 4 ↗
Oct 7	Oct 5	Mark Elliott BouldingGeneral Counsel	General Counsel	▼ SELL10b5-1	1,638	64.03	$105K	−1.5%	Form 4 ↗
Oct 7	Oct 6	Mark Elliott BouldingGeneral Counsel	General Counsel	▼ SELL10b5-1	435	64.16	$28K	−0.4%	Form 4 ↗
Oct 2	Sep 30	Steele Glenn Jr Md PhdDirector	Director	▼ SELL10b5-1	12,000	65.16	$782K	−35%	Form 4 ↗
Sep 18	Sep 17	Michael SchmertzlerDirector	Director (ind.)	▼ SELL10b5-1	10,000	67.85	$679K	−0.8%	Form 4 ↗
Sep 18	Sep 16	Michael SchmertzlerDirector	Director (ind.)	▼ SELL10b5-1	10,000	67.12	$671K	−0.8%	Form 4 ↗
Sep 11	Sep 9	Michael SchmertzlerDirector	Director (ind.)	▼ SELL10b5-1	10,000	67.84	$678K	−0.7%	Form 4 ↗
Sep 11	Sep 10	Michael SchmertzlerDirector	Director (ind.)	▼ SELL10b5-1	10,000	67.34	$673K	−0.8%	Form 4 ↗

Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings

All 15 PTCT insider trades →

Insiders who traded in the past year

Insider	Role	Bought	Sells	Sold	Latest
Michael Schmertzler	Director	$0	10	$6.62M	Oct 16, 2026
Mark Elliott Boulding	General Counsel	$0	4	$349K	Oct 13, 2026
Steele Glenn Jr Md Phd	Director	$0	1	$782K	Oct 2, 2026

Tracked funds that report PTCT

From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.

Fund	Quarter	Shares	Value	% of portfolio	Change
Renaissance Technologies	Q2 2026	723,500	$59.0M	0.08%	▲ +35.7%

Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings

Reading these numbers

Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →